Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis.

[1]  C. E. Pedreira,et al.  Evaluation of the WHO criteria for the classification of patients with mastocytosis , 2011, Modern Pathology.

[2]  A. Piskorz,et al.  Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis. , 2011, Experimental hematology.

[3]  T. Overbeck,et al.  Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis. , 2011, Journal of the American Academy of Dermatology.

[4]  A. Piskorz,et al.  A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib , 2011, European journal of haematology.

[5]  A. Tefferi,et al.  A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisions , 2010, European journal of haematology.

[6]  A. Órfão,et al.  Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. , 2010, The Journal of allergy and clinical immunology.

[7]  A. Tefferi,et al.  Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature , 2010, Current opinion in hematology.

[8]  H. Kantarjian,et al.  Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. , 2009, Leukemia research.

[9]  A. Órfão,et al.  Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. , 2009, The Journal of allergy and clinical immunology.

[10]  E. Iannitto,et al.  Advanced mast cell disease: an Italian Hematological Multicenter experience , 2008, International journal of hematology.

[11]  C. Urban,et al.  Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation. , 2008, Blood.

[12]  S. Hirota,et al.  Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation , 2007, Laboratory Investigation.

[13]  A. Órfão,et al.  KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. , 2006, Blood.

[14]  H. Kluin-Nelemans,et al.  Imatinib mesylate in the treatment of systemic mastocytosis , 2006, Cancer.

[15]  T. Lister,et al.  A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. , 2006, Leukemia research.

[16]  E. Wardelmann,et al.  Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. , 2005, Gastroenterology.

[17]  K. Wilson,et al.  Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase* , 2004, Journal of Biological Chemistry.

[18]  Cem Akin,et al.  A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. , 2004, Blood.

[19]  A. Órfão,et al.  Well-differentiated systemic mastocytosis: A new disease variant with mature mast cell phenotype and lack of codon 816 c-Kit mutations , 2004 .

[20]  D. Gilliland,et al.  CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. , 2003, Blood.

[21]  E. Baxter,et al.  Imatinib for systemic mast-cell disease , 2003, The Lancet.

[22]  B. Longley,et al.  Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. , 2003, Experimental hematology.

[23]  H. Kantarjian,et al.  Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. , 2003, Blood.

[24]  D. Gilliland,et al.  Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. , 2003, Blood.

[25]  E. Baxter,et al.  Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. , 2003, Blood.

[26]  L. Ashman,et al.  Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. , 2002, Molecular cancer therapeutics.

[27]  H. Kantarjian,et al.  Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. , 2002, Leukemia research.

[28]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[29]  Shan Zeng,et al.  The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. , 2002, Blood.

[30]  Schaller Jl,et al.  Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. , 2001 .

[31]  Y. Ma,et al.  Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. , 2001, Leukemia research.

[32]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[33]  D. Tuveson,et al.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.

[34]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[35]  J. Kiernan.  Production and life span of cutaneous mast cells in young rats. , 1979, Journal of anatomy.